TNFRSF17 and cancer: Various mAbs were used to bridge the extracellular portion of the CD16 CARs to the antigen expressed on cancer cells: rituximab, trastuzumab, and the humanized non-fucosylated IgG1 mAb targeting B-cell maturation antigen (SEA-BCMA) for the treatment of CD20-positive B cell lymphoma, HER2-positive solid tumors, and BCMA-positive MM, respectively (Table 5).